Tanezumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tanezumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target NGF
Clinical data
Legal status ?
Identifiers
CAS number 880266-57-9 N
ATC code None
UNII EQL0E9GCX1 YesY
Synonyms RN624
Chemical data
Formula C6464H9942N1706O2026S46 
Mol. mass 145.4 kDa
 N (what is this?)  (verify)

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]

In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.

References[edit]

http://www.medicalnewstoday.com/articles/242848.php

External links[edit]